Fu Su
Impact in
-
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
-
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 4
- Lymphatic System and Diseases 3
-
- Angiogenesis and VEGF in Cancer 3
- Co-authors
- Paul L. Beaumier (2 shared papers)Donald B. Axworthy (2 shared papers)Alan R. Fritzberg (2 shared papers)Robert W. Mallett (1 shared paper)Mark D. Hylarides (1 shared paper)J. M. Reno (1 shared paper)Louis Theodore (1 shared paper)Hazel B. Breitz (1 shared paper)
- Journals
- Journal of X-Ray Science and Technology (1 paper)Pathology & Oncology Research (1 paper)International Journal of Oncology (1 paper)Anti-Cancer Agents in Medicinal Chemistry (1 paper)Cancer Biotherapy and Radiopharmaceuticals (1 paper)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Fu Su
8 papers receiving 375 citations
Peers
Comparison fields: 5 of 53
- Radiology, Nuclear Medicine and Imaging 281
- Pathology and Forensic Medicine 74
- Oncology 82
- Cell Biology 35
- Neurology 29
Countries citing papers authored by Fu Su
This map shows the geographic impact of Fu Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fu Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fu Su more than expected).
Fields of papers citing papers by Fu Su
This network shows the impact of papers produced by Fu Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fu Su. The network helps show where Fu Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Fu Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 190 | |
| 2 | Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. | 2000 | 124 |
| 3 | 2015 | 25 | |
| 4 | 1996 | 15 | |
| 5 | 2015 | 13 | |
| 6 | 2019 | 12 | |
| 7 | 2016 | 9 | |
| 8 | 2019 | 2 |
About Fu Su
Fu Su is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Cellular and Molecular Neuroscience and Cell Biology, having authored 8 papers that have together received 390 indexed citations. Recurring topics across this work include Lymphatic System and Diseases (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Biotin and Related Studies (2 papers), Axon Guidance and Neuronal Signaling (2 papers), Cancer, Hypoxia, and Metabolism (1 paper) and Rheumatoid Arthritis Research and Therapies (1 paper). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (281 citations), Pathology and Forensic Medicine (74 citations), Oncology (82 citations), Cell Biology (35 citations) and Neurology (29 citations). Fu Su has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Paul L. Beaumier, Donald B. Axworthy, Alan R. Fritzberg, Robert W. Mallett, Mark D. Hylarides, J. M. Reno, Louis Theodore, Hazel B. Breitz, Paul L. Weiden and John M. Reno. Their work appears in journals such as Journal of X-Ray Science and Technology, Pathology & Oncology Research, International Journal of Oncology, Anti-Cancer Agents in Medicinal Chemistry and Cancer Biotherapy and Radiopharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.